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ABSTRACT 
Objective: Simultaneous quantification of Rosuvastatin and Fenofibrate tablets by HPTLC method was developed and validated as per International 
Conference on Harmonization [(ICH) Q2 (R1)] guideline. Methods: The chromatograms were developed using a mobile phase of ethyl acetate: acetic 
acid (20: 0.2, v/v) on aluminium pre-coated plates of silica gel G F254 of TLC plates and quantified by densitometric absorbance mode at 246 nm. 
Results: The R f
Keywords: Rosuvastatin, Fenofibrate, HPTLC, Validation, ICH Q2 (R1). 
 values were 0.31 ± 0.01 and 0.76 ± 0.01 for Rosuvastatin and Fenofibrate, respectively. The linearity of the method was found to be 
in the concentration range of 50-800 ng/band for both drugs. The limits of detection and quantification were 11.07 and 33.56 ng/band for 
Rosuvastatin and 12.76 and 38.68 ng/band for Fenofibrate. Conclusion: Developed densitometric method was found to be robust, precise, accurate, 
rapid and can be used to analyse fixed-dose tablet samples of Rosuvastatin and Fenofibrate. 
 
INTRODUCTION  
Rosuvastatin calcium (ROS) is official in Indian Pharmacopoeia [1]. 
Rosuvastatin calcium is chemically (E)-(3R, 5S)-7-{4-(4-
flurophenyl)-6-isopropyl-2-{methyl (methyl sulphonyl amino)] 
pyrimidine-5-yl}-3,5-dihydroxyhepten-6-oic acid calcium. ROS 
belongs to statin class of drugs used to treat hypercholesterolemia 
both in patients with established cardiovascular disease [2]. 
Fenofibrate (FEN) is official in British Pharmacopoeia [3]. 
Chemically, Fenofibrate (FEN) is Propan-2-yl 2-[4-(4-chlorobenzoyl) 
phenoxy]-2- methyl propionate is the lipid regulating drug [3 - 4]. 
The structures of both drugs are shown in Fig. 1.  
 
(A)                                (B) 
Fig. 1: Chemical structures of (A) Rosuvastatin (B) Fenofibrate 
 
A detailed survey of analytical literature for estimation of ROS alone 
or in combination with other drugs revealed several methods based 
on various techniques viz, HPLC [5-8], spectrophotometry [9-11] 
and high performance thin layer chromatography (HPTLC) [12-14]. 
Estimation of FEN was also reported in bulk and formulations using 
HPLC [15-17], Spectrophotometry [18, 19] HPTLC [20, 21] and other 
analytical methods reported on this combination are UV [22, 23], 
HPLC [24, 25]. But referring to the literature survey, there is no any 
published HPTLC method for Rosuvastatin calcium and Fenofibrate 
in combined tablet form. The present paper reports for the first time 
a HPTLC method for simultaneous estimation of Rosuvastatin 
Calcium and Fenofibrate in combined tablet dosage form. 
MATERIALS AND METHODS 
Pure ROS and FEN were kind gifts from Emcure Pharmaceuticals 
Limited, Pune, India. Commercial formulation (Arvast F Tablet, Intas 
Pharmaceuticals Limited) containing ROS (10 mg) and FEN (67 mg) 
were used for the study. All the chemicals used were of analytical grade 
(Merck specialities private limited, India). Aluminium plates pre-coated 
with silica gel 60 F254
Instrumentation and chromatographic conditions  
 were purchased from E. Merck, Darmstadt, 
Germany. Double distilled water was used in the present work.  
A Camag (Muttenz, Switzerland) TLC system equipped with 
Linomat-V sample applicator, Scanner-III, twin trough developing 
chamber (20 x 10 cm) and UV cabinet with dual wavelength (254 nm 
and 366 nm) UV lamp was used.  
The slit dimension was kept at 5 mm x 0.45 mm and 10 mm/s 
scanning speed was employed. Before using the plates were washed 
with methanol and activated at 110° C for 5 min. The mobile phase 
used was ethyl acetate: acetic acid (20: 0.2, v/v). Samples were 
applied to the plates as 6 mm bands.  
The chamber saturation time was 15 min at temperature 25 ± 20° C. 
The development distance was 8 cm. Plates were removed from 
chamber, dried by means of hot air, and the densitometric scanning 
was performed at 246 nm in absorbance-reflectance mode with 
winCATS software (1.4.4; Camag).  
Preparation of standard stock solutions  
Accurately weighed 10 mg Rosuvastatin calcium and Fenofibrate 
were dissolved and diluted with methanol up to 100 Ml, separately 
(100 μg/mL). These stock solutions were used for further analysis.  
Selection of detection wavelength  
Drug bands were scanned over the range of 200-700 nm and then 
UV-spectra were overlain. Both drugs showed significant 
absorbance at 246 nm and was selected for densitometric analysis.  
Preparation of sample solutions  
Twenty tablets were weighed the average weight was calculated and 
finely powdered. Tablet powder equivalent to 10 mg of ROS and FEN 
was accurately weighed and transferred to a 100mL calibrated 
volumetric flask. Around 50 mL of methanol was added, and the 
solution sonicated for 30 min. Volume was made up to the mark 
with the methanol. The solution was filtered through Whatman no.1 
filter paper. 
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Assay validation  
The developed HPTLC method was validated as per the International 
Conference on Harmonization (ICH) Q2 (Rl) guideline [26].  
Linearity and Range  
Calibration curves were plotted over the concentration range of 50-
800 ng/band for ROS and FEN. The HPTLC plate was developed and 
analyzed as described under the above chromatographic conditions. 
The calibration curve was prepared by plotting peak area versus 
concentration (ng/band) corresponding to each band. Each reading 
was an average of six determinations. To ascertain linearity, residual 
analysis was also performed.  
Limit of detection and limit of quantitation  
To check sensitivity, limit of detection (LOD) and limit of 
quantitation (LOQ) was determined by using formula 3.3 σ/S and 10 
σ/S, respectively. Where, σ is the standard deviation of the response 
(y-intercept) and S is the slope of the linearity plot.  
Specificity  
The specificity of the method was determined by analyzing standard 
drug and test samples. The band for ROS and FEN in the samples 
was confirmed by comparing the R f
Precision studies  
 and spectrum of the band with 
that of a standard. The peak purity of ROS and FEN was determined 
by comparing the spectrum at three different regions of the band i.e. 
peak start (S), peak apex (M) and peak end (E). 
The precision of the method was verified by repeatability and 
intermediate precision studies. Repeatability studies were 
performed by analysis of concentrations 100 ng/band for both ROS 
and FEN, six times on the same day. The intermediate precision of 
the method was checked by repeating studies on three successive 
days. 
Accuracy studies  
The accuracy of the method was determined by calculating 
recoveries of ROS and FEN by the standard addition method. Known 
amounts of standard solutions of ROS and FEN was added at 80, 100 
and 120 % level to sample solution of ROS and FEN (100 ng/band 
for ROS and FEN) 
Robustness studies  
In the robustness study, small but deliberate variations in the 
analytical operational parameters were done and its effects on the 
results were examined. Factors varied were mobile phase (ethyl 
acetate) composition (± 0.1 mL), amount of mobile phase (± 5 %), 
time from band application to chromatographic development (+ 10 
min) and time from chromatography to scanning (+ 15 min). At a 
time, one factor was altered. Concentration of 100 ng/band for both 
drugs in hexaplicates was used to study robustness of the 
densitometric method. The standard deviation of peak areas and % 
relative standard deviation (% RSD) were calculated. 
Solution stability 
The stability of ROS and FEN standard solutions (100 ng/band) was 
tested after 0, 6, 12, 24 and 48 h of storage at room temperature. The 
stability of the solutions was determined by comparing peak areas at 
each time hour against freshly prepared standard solutions. 
RESULTS AND DISCUSSION 
Development of the optimum mobile phase  
Initially, different solvent systems containing various ratios of 
dichloromethane, toluene, n-hexane, ethanol, methanol, water, ethyl 
acetate, and acetone were tried. Finally, the mobile phase consisting 
of ethyl acetate: acetic acid (20: 0.2, v/v) was selected as it gave 
sharp, symmetrical and well resolved peaks. The analytical 
wavelength (246 nm) was chosen on the basis of the absorption 
spectrum recorded in the range 200-800 nm. The retention factors 
were found to be 0.31 ± 0.02 and 0.76 ± 0.02, for ROS and FEN, 
respectively (Fig. 2).  
 
 
Fig. 2: Densitogram obtained from mixed standard solution of 
ROS and FEN scanned at 246 nm. 
 
Validation of the method  
Linearity and Range  
Linearity was observed by plotting standard drugs concentration 
against peak areas obtained. The results were found to be linear 
over a range of 20-800 ng/band for ROS and FEN.  
 
Table 1: Linear regression data for the calibration curves (n = 
6). 
Parameters ROS  FEN  
Linearity range (ng/band) 20-800 20-800 
r 0.999 2 0.999 
Slope 8.156 10.744 
Intercept 489.83 3026.5 
Confidence limit of slope 8.00-8.30 a 10.49-10.99 
Confidence limit of intercept 420.25-559.41 a 2923.0-3129.8 
S 27.38 y.x 41.57 
a95 % confidence limit, Sy.x
 
 - Standard deviation of residuals from 
line. 
To ascertain linearity, residual analysis was performed (Fig. 3). 
Slope was significantly different from zero. 
 
 
Fig. 3: Concentration residual plot of (A) Rosuvastatin  
 
Sensitivity  
The LOD and LOQ were found to be 11.07, 12.76 ng/band and 33.56, 
38.68 ng/band for ROS and FEN, respectively, representing good 
sensitivity of the method.  
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Specificity  
The peak purity of ROS and FEN was assessed by comparing the spectra 
of standard at peak start, peak apex and peak end positions of the band 
i.e., r (start, middle) = 0.998, and r (middle, end) = 0.9993 respectively. 
Hence, peaks obtained for ROS and FEN were pure. 
 
Fig. 3: Concentration residual plot of (B) Fenofibrate 
 
Precision  
The developed method was found to be precise, with % RSD values 
for repeatability and intermediate precision studies below 2 % as 
recommended by ICH Q2 (R1) guideline (Table 2). 
Accuracy  
Recoveries of ROS and FEN were found to be 100.66-102.21 % and 
99.58-101.58 %, respectively which indicates that the proposed 
simultaneous densitometric method is reliable for the estimation of ROS 
and FEN in the marketed formulation used in the study (Table 3) 
Robustness studies  
The % RSD of peak areas was calculated for each parameter and was 
found to be less than 2 % (Table 4). 
 









Rosuvastatin 100   99.06/98.74 0.74/0.93 
Fenofibrate 100   98.52/99.34 0.49/0.68 
n = Number of determinations; a = ng/band; RSD = Relative 
standard deviation 
 
Solution Stability  
Stability of standard solution of ROS and FEN were evaluated at 
room temperature for 48 h. The % RSD was found to be below 2.0 % 
indicating both standard and sample solutions were stable up to 48 
h at room temperature. 
Analysis of marketed formulation  
Proposed HPTLC method was applied for analysis of tablet dosage 
form viz, Myotop tablets in six replicate determinations. The % assay 
was found to be 100.47 and 99.84 % for ROS and FEN, respectively.
 
Table 3: Results of recovery studies (n=6) 
Amount added Amount found a a % Recovery ± % RSD  ± SD 
ROS FEN ROS FEN ROS FEN 
80 80 180.98 ± 1. 52 181.40 ± 1.35 100.54 ± 0.83 100.77 ± 0.64 
100 100 201.86 ± 1.15 199.77 ± 1.20 100.98 ± 0.70 99.88 ±1.33 
120 120 121.33 ± 1.08 119.96 ± 1.74  101.10 ± 0.52 99.96 ± 0.61 
n = Number of determinations; a = ng/band; SD = Standard deviation; RSD = Relative standard deviation 
 
Table 4: Robustness testing (n =6, 100 ng/band) 
Parameter varied SD of peak area % RSD 
 ROS FEN ROS FEN 
Mobile phase (Ethyl acetate) composition (± 0.1 mL) 12.01 28.79 0.90 0.69 
Amount of mobile phase  
(± 5 %) 
13.59 21.9 1.01 0.52 
Time from band application to chromatography 
(+ 10 min) 
11.61 30.52 0.87 0.73 
Time from chromatography to scanning (+ 15 min) 13.34 31.70 1.005 0.76 
n = Number of determinations; SD = Standard deviation; RSD = Relative standard deviation 
  
CONCLUSION  
In the present research work, attempt has been made to develop and 
validate new, rapid, precise, accurate, and robust densitometric method 
for simultaneous quantification of ROS and FEN in the tablet formulation. 
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